Strides Pharma Science Ltd announced on September 8 that its Singapore-based subsidiary, Strides Pharma Global Pte. Limited, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc., a contract development and manufacturing organization specializing in orally inhaled and nasal drug products (OINDPs). The collaboration focuses on developing and filing multiple nasal spray products for the US market across diverse therapeutic indications.
Strategic Focus on Nasal Spray Technology
The partnership reinforces Strides' commitment to nasal spray technology, which the company has consistently highlighted as a key focus area. Under the agreement, Kenox will provide its specialized expertise in formulation and development to support Strides in creating and filing regulatory approvals for multiple nasal spray products. Specific product details remain confidential at this stage.
"We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space," said Aditya Kumar, Executive Director Business Development at Strides Pharma Science Limited. "Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain."
Complementary Capabilities Drive Market Expansion
The alliance leverages the complementary strengths of both organizations. Strides brings established manufacturing capabilities and market reach, while Kenox contributes specialized technical know-how in OINDP development. Kumar emphasized that with continued investments in capabilities and capacities at Strides' US facility, nasal spray products represent a natural fit within the company's strategy to expand its nasal spray technology domain.
"Kenox's formulation and development strengths perfectly complement our manufacturing and go-to-market strengths allowing us to accelerate our range of nasal spray offerings in the US market," Kumar added.
Validation of OINDP Expertise
For Kenox, the partnership represents significant validation of its specialized capabilities. Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc., described the collaboration as "a significant milestone for Kenox."
"This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price," Dr. Velaga stated.
Market Impact and Therapeutic Access
The partnership is expected to accelerate the development pipeline of nasal spray products for the US market, with both companies emphasizing their commitment to delivering affordable, high-quality therapies to patients. The collaboration positions Strides to deepen its penetration of the US nasal spray market by combining Kenox's technical strengths with Strides' manufacturing and distribution capabilities.
The strategic alliance reflects Strides' broader focus on innovation and its ambition to expand its presence in the regulated US pharmaceutical market, particularly in the specialized area of nasal drug delivery systems.
